The Indian Pharmaceutical Market (IPM) has posted strong growth of 12.7 per cent during July 2018 and touched to Rs.10,616 crore. Last year, due to GST roll out, the market slumped to a de-growth of 2.4 per cent and sales worth Rs.9,280 crore.
According to an AIOCD AWACS report, in the month of July 2018 the volumes have posted a positive growth however price component is showing a positive impact due to the GST roll out in July 2017 (which lead to lower price as the excise component being absent). MNCs achieved growth of 10.2 per cent, while India companies moved faster at 13.4 per cent.
From therapy perspective 17 therapies have shown a positive growth. All the chronic therapies like anti-diabetic, cardic, and CNS have posted growth of 18.5 per cent, 15.5 per cent and 14.2 per cent respectively. Similarly, anti-infectives has shown a growth of 8 per cent as against de-growth of 15.7 per cent in similar month of last year. Dermatology growth has jumped to 18 per cent and respiratory clocked growth of 8.1 per cent. Gastro intestinal has shown a growth of 10.7 per cent and vitamins are also moved up 12.7 per cent.
FDC related market showed growth of 5.2 per cent while the non FDC market showed a growth of 12.1 per cent. Single molecules grew at 13.5 per cent for the month of July 2018. Price component of GD for the FDCs remained at 5.8 per cent, other GDs in terms of volumes declined by one per cent while new products grew at 0.4 per cent.
Amongst the top 10 corporate, Lupin has the highest growth at 19.6 per cent followed by Alkem at 17.8 per cent and Torrent Pharma at 18.3 per cent. Out of top 50 companies, 48 companies achieved positive growth during July 2018. Boehringer Ingelheim has the highest growth of 31.9 per cent followed by Micro Labs growing at 29.5 per cent and Glenmark at 26.6 per cent. Sun portfolio has shown a growth of 15.2 per cent while Ranbaxy has a growth of 8 per cent. However, Emcure and Zuventus have slowed down during July 2018.
Total 15 companies launched in last three years, and out of this 2 companies registered sales of over Rs.10 crore. In the non-NLEM category Indian companies showed a growth of 14.1 per cent whereas MNCs grew at 11.7 per cent. The NLEM 2013 containing molecules market showed growth at 5 per cent whereas the non NLEM market grew by 13.6 per cent resulting in an overall growth of 12.7 per cent for the months of July 2018.
Overall 29 regions have posted positive growth for month of July 2018. Bihar market grew the highest at 30.1 per cent followed by West Bengal at 27.2 per cent and North at 24.1 per cent.
Amoxycillin plus clavulanic acid market grew by 7.4 per cent to Rs.147.2 crore and glimepiride plus metformin market moved up by 12.1 per cent to Rs.183.5 crore. Azilsartan plain market is valued at Rs.69.6 crore on MAT basis and sofosbuvir and its combination market has reached at Rs.614.4 crore. The luliconazole market is worth 326.9 crore while tenegliptin and its combinations are value at Rs.743.1 crore. The market of paracetamol plain is growing double digit at 14.3 per cent on monthly basis, plain atorvastatin has posted a growth 11.6 per cent.
Among the major brands, Mixtard has posted monthly sales worth Rs.46 crore while Spasmoproxivon plus has registered sales of Rs.50 crore. Glycomet GP is at Rs.39 crore, Lantus is at Rs.34 crore and Galvus met at Rs.33 crore. Liv 52 reached at Rs.26 crore, Janumet at Rs.36 crore and Augmentin at Rs.26 crore during July 2018.
Among the new launch molecules, Azisartain and combinations are now valued at Rs.73.5 crore. On MAT basis with Zilarbi (Emcure) leading followed by Abel (Lupin) and Aztric (Intas). Luliconazole segment is worth Rs.326.9 crore on MAT basis and there are already 57 new brands launched in the segment.
Within the VMS category there have been 13 brands launched for the months of July 2018. Within cardiac there have been 9 brands launched and within derma there were 15 brands launched in July 2018. In gastro segment total 19 new brands wee launched and in anti-infectives 20 new brands were launched